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Mucolipidosis type IV (MLIV, MIM 252650) is an autosomal recessive lysosomal storage disorder that causes mental and motor retardation as well
as visual impairment. The lysosomal storage defect in MLIV is consistent with abnormalities of membrane traffic and organelle dynamics in the late
endocytic pathway.MLIVis caused bymutations in theMCOLN1 gene, which codes for mucolipin-1 (MLN1), a member of the large family of transient
receptor potential (TRP) cation channels. Although a number of studies have been performed on mucolipin-1, the pathological mechanisms underlying
MLIVare not fully understood. To identify genes that characterize pathogenic changes inmucolipidosis type IV, we compared the expression profiles of
threeMLIVand three normal skin fibroblasts cell lines using oligonucleotidemicroarrays. Genes thatwere differentially expressed in patients' cells were
identified. 231 geneswere up-regulated, and 116 down-regulated. Real-Time RT-PCR performed on selected genes in six independentMLIV fibroblasts
cell lines was generally consistent with the microarray findings. This study allowed to evidence the modulation at the transcriptional level of a discrete
number of genes relevant in biological processeswhich are altered in the disease such as endosome/lysosome trafficking, lysosome biogenesis, organelle
acidification and lipid metabolism.
© 2008 Elsevier B.V. All rights reserved.Keywords: Mucolipidosis type IV; Lysosomal diseases; Microarray; Gene expression profiling; Gene ontology1. Introduction
Mucolipidosis type IV (MLIV, MIM 252650) is an autosomal
recessive lysosomal storage disease that causes severe neurologic
abnormalities, achlorhydria, and visual impairment including
corneal opacity, retinal degeneration, strabismus [1]. MLIV was
first recognized in 1974 [2] and it predominantly affects people
of Ashkenazi Jewish (AJ) origin, with an estimated frequency of
1/40,000 and heterozygote frequency of 1/100 [3,4]. The disease
manifests itself in infancy, but is characterized by a slow progress,
withmost patients remaining in an apparent steady state for two to
three decades.
Electron microscopy observations demonstrated lysosomal
storage of both amphiphilic lipids in the shape of multi-concentric⁎ Corresponding author. Tel.: +39 030 3717232; fax: +39 030 3701157.
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doi:10.1016/j.bbadis.2008.01.002lamella together with granulated, water-soluble substances.
Chemical analysis indicated that the storage materials, found in
all the cells examined in MLIV patients, consisted mainly of
phospholipids, gangliosides, neutral lipids, andmucopolysacchar-
ides [5]. The disease was thus classified as a mucolipidosis. In-
terestingly, the storage bodies observed in MLIV fibroblasts are
autofluorescent [6]. Studies with radioactive lipids (phosphati-
dylcholine or various gangliosides), or by fluorescent lipid an-
alogues exogenously added to cultured fibroblasts indicated a
significant retention of these compounds in lysosomes of MLIV
patients during the pulse periodwhen compared to normal control.
However these substances were degraded during chase periods
at a normal rate and pattern [7,8] indicating that no defective
hydrolytic activity was responsible for this heterogeneous storage.
Analogue studies demonstrated a defective endocytosis process in
MLIV cells [9,10]. These observations imply that the lysosomal
storage in MLIV might stem from a defect in the endocytic
transport of membrane components, apparently as a result of a
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route to the final lysosomal vacuole destination. The loss of bal-
ance between transport of components into lysosomes and their
catabolism offers an explanation for the heterogeneous nature of
the stored molecules and the absence of organomegaly or skeletal
deformations seen in many other lysosomal storage diseases.
Nevertheless, it should be emphasized that changes in the
endocytic trafficking of lipid analogues were observed in other
lysosomal storage disorders [11].
MLIV is caused by mutations inMCOLN1, a gene mapping to
19p13.3 [12–15] encoding mucolipin-1 (MLN1), a 580-amino
acid protein with six predicted transmembrane domains. MLN1
presents a transient receptor potential (TRP) cation channel do-
main and an internal calcium and sodium channel pore region.
The TRP domain spans transmembrane segments 3–6, with the
putative pore-forming loop between the fifth and sixth segments.
Two di-leucine motifs regulate trafficking of mucolipin-1 to
lysosomes [16]. Overexpressedwild typemucolipin-1 colocalizes
to late endocytic structures and induces an aberrant distribution of
these compartments [17]. Two recent studies, suggest a novel role
for MLN1 in regulating lysosomal function [18–20]. When intact
in the lysosomes, mucolipin-1 provides a H+ leak pathway to
prevent over-acidification of the lumen. When further acidifica-
tion is needed to activate lipases, proteases or other lysosomal
functions, MLN1 is then cleaved by a CatB dependent pathway
that may be activated by very acidic lysosomal pH (pHL). Con-
tinue insertion and cleavage ofMLN1 results in cycles of decrease
and increase in pHL that is needed for the normal functioning of
lysosomal lipases. MLIV associated mutations in mucolipin-1
disrupt regulation of pHL and lead to aberrant activity of lysosomal
lipases and the MLIV phenotype. MLN1 biological role seems to
be highly conserved during evolution. A loss-of-functionmutation
in the Caenorhabditis elegans mucolipin-1 homologue, cup-5,
was shown to result in decreased degradation of endocytosed
protein and accumulation of large vesicles [21]. Overexpression of
this protein caused the opposite phenotype, suggesting a role for
CUP-5 in the regulation of endocytosis. More recent studies
demonstrated that CUP-5 functions in the biogenesis of lysosomes
originating from hybrid organelles [22].
The aim of this study is to gain further insight into the MLIV
phenotype through the use of the DNA microarray technology.
The comparison of the gene expression profiles of culturedMLIV
fibroblasts and healthy ones allowed us to identify a substantial
number of differentially expressed genes, many of which have
been shown to be relevant for the physiology and the biogenesis
of the lysosomal compartment.
2. Materials and methods
2.1. Cell Lines
For expression profiling studies, GM02527 and GM02529 MLIV fibroblasts
cell lines were obtained from the Coriell Cell Repositories (CRC), Camden, NJ,
whereas for MLIV patient FM001 dermal fibroblasts have been obtained through
external clinical collaborators. All patients gave their written informed consent.
GM02527 is homozygous for an A→G transition at the 3′ acceptor site of intron 3
(486-2A→Gmutation), resulting in skipping of exon 4; GM02529 is a compound
heterozygote for a 6432-bp genomic deletion spanning a region from the 5′ end of
the gene to the first 12 bp of exon 7 and for 486-2A→G splicingmutation; FM001carries a 525insT frameshift allele which encodes a truncated protein of 148 aa. The
control fibroblasts cell lines AB12, AB13 and AB14 have been derived from three
different normal individuals.
Three additional fibroblast cell lines derived from MLIV patients (GM02526,
GM02528, GM02629) were ordered from CRC and included in Real-Time PCR
validation studies. The number of passages in tissue culture were comparable
(ranging from 17th to 20th passage) among the fibroblast cell lines used in our
study. Fibroblast cells were seeded in 175-cm2 tissue culture flasks (Falcon),
maintained in Eagle's minimum essential medium (MEM) (Euroclone Life
Sciences), supplemented with 20% (v/v) fetal bovine serum (HyClone), 100 U/ml
penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (Invitrogen Life Tech-
nologies) at 37 °C in a 5% CO2 humidified incubator. When the monolayer of
adherent cells has reached confluence, they were trypsinized (0.25% trypsin;
Sigma) and pelletted for the subsequent RNA extraction.
2.2. RNA extraction
Total RNAwas isolated fromconfluent cells using Phase LockGel (Eppendorf)
in conjunction with TRIzol (Invitrogen, Life Technologies) reagent according to
manufacturers' protocols. The RNAwas quantified using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Inc.) and checked for quality control
with Agilent Bioanalyzer 2100 (Agilent Technologies). We routinely obtain a total
RNAwith a 260/280 absorbance ratio of approximately 1.9.
2.3. Target preparation and microarray hybridization
We pooled in a single tube equal amounts of the total RNA obtained from the
three MLIV cell lines (MLIV pool). Similarly we created a pool starting from the
RNAs of the fibroblasts of three normal individuals (AB pool). The cDNA target
was generated using the First Strand cDNA Synthesis Kit (Amersham Bio-
sciences), by direct incorporation of fluorescent nucleotide analogues during
reverse transcription reaction. Briefly, for each labeling experiment 20 μg of total
RNA were primed with anchored oligo(dT), incubated at 70 °C and cooled for
5 min at 4 °C. The RNA was reverse transcribed using the CyScript reverse
transcriptase enzyme with dUTP nucleotide mix either with Cy3-dUTP or Cy5-
dUTP (MLIV pool was Cy5 labeled, whereas AB pool was Cy3 labeled) and
incubated at 42 °C for 3 h. Following cDNA synthesis and labeling, RNA was
degraded by RNase H (Roche Applied Science) treatment at 37 °C for 20 min,
alkaline hydrolysis with 2.5M NaOH (Sigma) for 15 min at 37 °C and neutralized
with 2MHEPES (Sigma). Tominimize hybridization background and improve the
sensitivity of detection of low abundance targets, unincorporated CyDye-
nucleotides were removed from the reaction using the Qiaquick PCR purification
kit (Qiagen). The cDNA was recovered in 60 μl of elution buffer. Labeling
efficiency was assessed with the microarray module software of the NanoDrop
ND-1000 spectrophotometer. For each hybridization, Cy3- and Cy5-labeled
transcripts were mixed together using an equal amount of each label, assuming that
the control and experiment targets were both labeled at about the same nucleotide/
dye ratio. The mixed cDNAs were dried using a Microcon column (Millipore).
2.4. Human oligo arrays
The gene expression profile study was carried out using the Human 21K oligo
arrays (Operon oligonucleotide set version 2.0) comprising 21,329 70-mer
oligonucleotides designed from the UniGene build Hs 147 (February 2002). The
oligonucleotides have been spotted in duplicate on MICROMAX glass slide
SuperChip I (Perkin Elmer Life Sciences) at C.R.I.B.I. center of PadovaUniversity
(http://microcribi.cribi.unipd.it/). Additional information on these microarrays can
be found at the same URL.
2.5. Oligo array hybridization
Slides were pre-hybridized at 42 °C for 3 h with a buffer composed by 5× SSC,
0.1% SDS, 100 ng/μl salmon sperm DNA (Invitrogen, Life Technologies), 5×
Denhardt's solution. Then the slides were washed with MilliQ water and dried by
centrifugation. 50 μl of hybridization mixture, composed by 250 ng poly(dA)
(Amersham Biosciences), 50% deionized formamide and 25% Hybridization
Buffer Version 2 (Amersham Biosciences), was added to dried labeled cDNA,
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microarray slides was accomplished under a lifter slip (Implen GmbH) in a
hybridization chamber (Genetix) at 42 °C for at least 18 h. Post hybridization
washes were performed at room temperature for 5 min each in 1× SSC, 0.1% SDS;
0.1× SSC, 0.1% SDS; 0.2× SSC and transferred to 0.1× SSC for 2min. Slideswere
dried by centrifugation.
2.6. Data acquisition and analysis
A confocal dual laser scanner (VersArray ChipReader, Bio-Rad Laboratories)
was used to acquire the hybridization data at a 5 μm of resolution. Laser strength
and sensitivity detectors settings were selected in order to obtain a balanced signal
ratio of Cy5 and Cy3 channels. Each pair of 16-bit TIFF files was processed using
the GenePix Pro 4.1 software (Axon Instruments). These files were firstly
examined for quality control: spots showing no signal or obvious defects were
accordingly flagged by GenePix Pro and excluded from further analysis, as well as
all control spots. All statistical and graphical analysis were carried out in the R
computing environment (http://www.R-project.org) using the Linear models for
microarray data package (Limma) [23] which is part of the Bioconductor project
(http://www.bioconductor.org/) [24]. For each microarray, a local background
subtraction was performed followed by global lowess normalization within each
slide. The box plot analysis showed that between arrays normalization was
necessary in order to obtain the best approximate equivalence among all the arrays
in study [25]. Therefore each arraywas scaled so that the log transformed ratios had
the same median absolute deviation [25]. The two replicate spots present for every
gene in the arrays were used to maximize the robustness of statistical analysis via
the “lmFit” function within Limma [23]. This procedure uses a pooled correlation
value to generate a more robust estimate of gene expression across replicate spots,
compared to a straight average of replicate spots. To assess the significance of up-
or down-regulation of the genes betweenMLIVandAB sample pools, an empirical
Bayesian (EB) method (B-test) [23] followed by moderated t-statistics with
adjusted p-values (FDR adjustment) [26], implemented in Limma, were applied.
Genes were then ranked as being differentially expressed in decreasing order of the
B-statistic (essentially the log-odds of differential expression) and p-value. A cut-
off for differentially expressed genes was best determined empirically through
volcano plot analysis which allows evaluating when selected genes are well sepa-
rated from the data cloud [27].We choose those geneswithBN=1, p-valueb=0.01
and MN=1 or Mb=−1 as “up-regulated” and “down-regulated” respectively.
Chromosomal distribution of differentially expressed genes was tested using the
ChrEx software (unpublished).
2.7. Gene ontology
To classify genes according to standardized Gene Ontology (GO) vocabulary
for the categories of biological processes, molecular functions and cellular
components, the entire dataset of differentially expressed genes (up- and/or down-
regulated) was imported into gene ontology software tools such as EASE (http://
david.niaid.nih.gov/david/ease.htm) [28] and Onto-Express (http://vortex.cs.
wayne.edu/projects.htm) [29]. OE automatically translates the non redundant
dataset using standardizedGO terms for cellular component, biological process and
molecular function providing statistical significance results for each category. GO
groupings were determined by comparing the number of genes expected for each
GO category based on their representation on the array. Significant (p-value b0.05)
differences from the expected were calculated by binomial test with a FDR-
corrected significance for the dataset analyzed.
2.8. Real-time RT-PCR
We used quantitative Real-Time RT-PCR to validate the results obtained from
microarray experiments, focusing our attention on a limited number of selected
genes. One microgram of total RNA from fibroblast cell lines was dissolved in
20 μl of final volume reactionmixture. Briefly the RNAwas incubatedwith 50 μM
oligo(dT)20 and 10 mM dNTP mix (Invitrogen, Life Technologies) at 65 °C for
5 min and at 4 °C for 3 min. A reaction mixture was added containing: 10× RT
buffer, 25 mM MgCl2, 0.1 M DTT, 200 U SuperScript III RT, 40 U RNaseOUT
(Invitrogen, Life Technologies). An identical reaction without reverse transcriptase
was performed to verify the absence of genomic DNA (no-RT control). Themixture was incubated at 50 °C for 50 min, followed by 5 min at 85 °C for to
inactivate the reverse transcriptase. 2 U of RNase H was added to each tube and
incubated for 20 min at 37 °C to remove the RNA template from the cDNA:RNA
hybrids. The final reaction's volume was set to 100 μl. Real-Time RT-PCR was
performed using the ICycler iQ detection system (Bio-Rad Laboratories). The PCR
cycling protocol was optimized to maximize the reaction efficiency and ensure that
only the target product was contributing to the SYBR Green fluorescence signal.
For each quantification, a standard curve was created using suitably appropriate
quantity of cDNA obtaining amplification efficiencies values close to 2 for all
primer combinations.
Reactions were performed in a 25 μl reaction volume, containing a variable
concentration (from 200 to 400 nM) of specific primers, 12.5 μl iQ SYBR Green
Supermix (Bio-Rad Laboratories), and 2 μl of reverse transcription reaction
solution. The amplification profile used was: denaturation program (95 °C for
3 min), 35 cycles of two steps amplification (95 °C for 15 s and 60 °C for 30 s), and
melting curve (60–90 °C with a heating rate of 0.5 °C/10 s). Each reaction was
performed in triplicate. Gene specific primers were designed with the Primer3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), using pub-
lished sequence data from theNCBIReference Sequence (RefSeq) database (http://
www.ncbi.nlm.nih.gov/RefSeq), and Oligo Analyzer software (http://www.idtdna.
com/analyzer/Applications/OligoAnalyzer/) to avoid potential hairpin formation
and self dimerization. Primer sequences are listed in Supplementary Table S1. Gel
electrophoresis and the dissociation curve were used to assess the specificity of the
amplicon (data not shown). To evaluate differences in gene expression we chose a
relative quantification method based on the standard curve approach as described
by Pfaffl, M.W. [30]. Levels of expression obtained by this method were
normalized with that of an endogenous control transcript glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) for MLIV pool versus AB pool comparison
and ribosomal protein, large, P0 (RPLP0) for GM02527, GM02529, FM001,
GM02526, GM02528, GM02629 versus AB pool comparison) that does not
appear to be differentially expressed under the experimental conditions assayed in
our work.
3. Results and discussion
In this study we exploited DNA microarray technology to
compare the gene expression profiles of cells from individuals
affected by mucolipidosis type IV and healthy controls. The
analysis was carried out on skin fibroblasts cell lines derived from
three different MLIV patients and three normal individuals. The
study of gene expression profiles in a genetic disease is often
impaired by the lack of suitable biological material from the
patients as source of RNA. In the case of MLIV, MCOLN1, the
gene mutated in the disease, is ubiquitously expressed and,
although psychomotor retardation is the most relevant phenotypic
consequence of MLIV, tissues other than brain are affected in the
disease, such as skeletalmuscles, cornea, retina, pituitary gland.A
relevant number of researches (described in the Introduction)
have been performed on fibroblasts of affected individuals dem-
onstrating bothmetabolic and structural alterations with respect to
normal controls. MLIV fibroblasts thus represent a suitable cell
type for expression profiling experiments that may ultimately
provide a global picture of the molecular changes occurring in
patients' cells. Pooling of RNA samples was performed to reduce
the genetic and biological variability that may occur within
individuals. The pooling strategy for microarray analysis presents
both advantages and disadvantages as described in a discrete
number of publications [31–33]. Since our main goal is to gen-
erate the first global picture of the transcriptional changes oc-
curring in MLIV rather then comparing the expression profiles of
individual patients, we believe that pooling of biological samples
is a suitable strategy for our study.
Fig. 1. Volcano plot of statistical significance versus gene expression ratio. Values were plotted for the B and M for each transcript expressed on the array. The
horizontal line, in bold, indicates B=0 and the bold vertical lines the 2-fold threshold. Black symbols represent changes below the threshold, red and green symbols
represent significant changes above the threshold. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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with the Operon Human Genome Array-Ready Oligo Set (Version
2.0) comprising 21,329 70-mer oligonucleotides representing the
same number of genes. Oligo array hybridization, washes and
scanning were performed as described in theMaterials and methds
section. Analysis of four technical replicates was performed using
the Limma package. The microarray data were prepared according
tominimum information about amicroarray experiment (MIAME)
recommendations [34] and deposited in the public GEO database
(http://www.ncbi.nlm.nih.gov/geo/). The GEO accession number
for Micro-CRIBI Human Oligo Array platform is GPL2136 and
for expression dataset is GSE5444.
From now on, the terms “up-regulated” or “overexpressed”
will indicate genes that are expressed more than two-fold (BN=1
and p-valueb=0.01) in MLIV fibroblasts than in the pool of
normal control cells. Vice versa, genes expressed more than two-
fold in normal control cells (using the same statistical criteria
indicated above) are defined “down-regulated”. This analysis led
to the identification of 231 up-regulated and 116 down-regulated
transcripts. To better visualize the results, a volcano plot of the
B against M values was generated (Fig. 1). No chromosomal-
skewed distribution was observed for differentially expressed
genes (data not shown).
3.1. Validation of microarray data
We used Real-Time RT-PCR to test the consistency and
reproducibility of the DNA microarray data. The study has been
carried out on a set of selected differentially expressed genes:
LAPTM5, LAPTM4A, CD63, CTSK, MANBA, ATP6V0E and
VPS39 encode proteins belonging to the lysosomal compartment
and are up-regulated inMLIV fibroblasts; LDLR and SREBF2 are
involved in lipid metabolism and are also up-regulated in MLIV;
FADS2, one of the genesmore up-regulated identified in our study
and POSTN, down-regulated in MLIV. The Real-Time PCR data
have been generated from the same MLIV and AB (normal
controls) RNA pools used for microarray expression profilingstudies. The data from triplicate experiments were quantified, and
the expression ratios of genes between theMLIV pool and the AB
pool were calculated and compared with the array data (Fig. 2).
There is a general agreement between the Real-Time PCR and
DNAmicroarray datasets even if, as previously reported by other
investigators, the differential expression values obtained using the
two techniques are not identical. The same genes were also
studied by Real-Time PCR on the RNA from skin fibroblasts of
six different MLIV patient's (the three included in gene expres-
sion profiling studies plus three additional ones). The majority of
the genes we tested behave similarly (Fig. 2) suggesting a limited
variability of gene expression among the different MLIV samples
present in our study. These results further support the effective-
ness of the RNA pooling strategy for microarray experiments on
MLIV fibroblasts.
3.2. Analysis of the differentially expressed genes
To facilitate the analysis of the differentially expressed genes
identified, we used the publicly available software Expression
Analysis Systematic Explorer (EASE) (http://david.niaid.nih.gov/
david/ease.htm) [28] which allows to automate the process of
creation of descriptive annotation tables. Furthermore, to translate
the data into a more meaningful biological context and to char-
acterize more thoroughly sets of functionally related genes, the
differentially expressed datasets were subsequently organized into
Gene Ontology (GO) groupings using the Onto-Express (OE)
software (http://vortex.cs.wayne.edu/projects.htm) [29]. The
results of the Onto-Express analysis are presented in Tables 1–4.
Tables 1 and 2 report the Gene Ontology classification (cellular
component category) for up- and down-regulated gene datasets,
respectively. The biological process GO categories for up-
regulated and down-regulated genes are shown in Table 3 and 4,
respectively. The output of the EASE and Onto-Express software
allowed us to manually curate a list of differentially expressed
genes (either up- or down-regulated in MLIV fibroblasts) that are
involved in important biological and molecular processes that are
Fig. 2. Validation of microarray data by Real-Time RT-PCR. Real-Time RT-PCR for selected differentially expressed genes has been carried out on total RNA of
“MLIV pool”, individual MLIV cell lines and “AB pool” (normal controls). The relative expression is represented as the mean±SEM, in 2log scale between “MLIV
pool” vs “AB pool” together with the microarray data obtained comparing the same biological samples. The figure also shows the relative expression of the selected
genes between individual MLIV cell lines (GM02527, GM02529, FM001, GM02526, GM02528 and GM02629) vs the “AB pool”. For all genes tested, with the
exception of those marked with an asterisk, the results obtained were statistically significant (pb0.05) based on Student's t test.
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findings is discussed below for every Gene Ontology category
present in Table 5.
3.3. Lysosomal genes
In our study we have identified a number of differentially
expressed genes that are related to the physiology of these
organelles.
The only down-regulated gene in this category is scavenger
receptor class B, member 2 (SCARB2), encoding a type III gly-
coprotein located primarily in limiting membranes of lysosomes
and endosomes that may participate in membrane transportation
and the reorganization of endosomal/lysosomal compartment.Table 1
Gene Ontology classification for up-regulated gene dataset
Cellular component Genes p-value
Integral to membrane 48 5.25E-03
Plasma membrane 14 3.05E-02
Extracellular matrix 12 1.45E-04
Endoplasmic reticulum 12 1.95E-02
Lysosome 9 1.58E-04
Proton-transporting two-sector ATPase complex 5 1.28E-03
Golgi apparatus 4 2.00E-02
Gene Ontology classification performed by Onto-Express software. We reported
only significative cellular components categories ( p-valueb0.05) and with a
number of genes greater than 3.Twelve genes belonging to the lysosomal compartment cate-
gory are up-regulated. Interestingly, a number of them are involved
in the pathogenesis of autosomal recessive lysosomal storage
disorders. Mannosidase, beta A, lysosomal (MANBA) encodes a
protein involved in the pathway for N-linked glycoprotein oligo-
saccharide catabolism. Mutations in this gene are associated with
beta-mannosidosis. Iduronidase, alpha-L- (IDUA) encodes an en-
zyme that hydrolyzes the terminal alpha-L-iduronic acid residues
of two glycosaminoglycans, dermatan sulfate and heparan sulfate.
IDUA mutations lead to mucopolysaccharidosis Type I (MPS I).
Another enzyme encoding gene is the Hexosaminidase B (HEXB);
mutations in this gene lead to an accumulation of GM2 ganglioside
in neurons and neurodegenerative disorders termed Sandhoff
disease. CLN2 and CLN3, encode proteins that are important in
lysosomal function: mutations in these, as well as other neuronal
ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative dis-
eases commonly known as neuronal ceroid-lipofuscinoses (NCLs).
CathepsinK (CTSK) gene encodes amember of the papain cysteineTable 2
Gene Ontology classification for down-regulated gene dataset
Cellular component Genes p-value
Cytoplasm 15 1.09E-02
Extracellular matrix 6 7.72E-03
Gene Ontology classification performed by Onto-Express software. We reported
only significative cellular components ( p-valueb0.05) and with a number of
genes greater than 3.
Table 3
Gene Ontology classification for up-regulated gene dataset
Biological process Genes p-value
Signal transduction 24 3.43E-02
Cell adhesion 14 4.24E-03
Protein amino acid phosphorylation 11 4.49E-02
Lipid metabolism 9 3.73E-03
Ion transport 7 3.91E-02
ATP synthesis coupled proton transport 5 1.14E-03
Phosphate transport 5 3.85E-03
Phospholipid biosynthesis 4 1.29E-03
Cholesterol metabolism 4 1.67E-03
Endocytosis 4 1.08E-02
Blood coagulation 3 1.90E-02
Gene Ontology classification performed by Onto-Express software. We reported
only significative biological processes ( p-valueb0.05) and with a number of
genes greater than 3.
Table 4
Gene Ontology classification for down-regulated gene dataset
Biological process Genes p-value
Cell adhesion 11 8.691E-04
Protein folding 6 1.277E-03
Integrin-mediated
signaling pathway
5 2.106E-05
Immune response 5 1.508E-02
Induction of apoptosis 4 2.068E-03
Cell motility 4 4.658E-03
Protein biosynthesis 4 1.929E-02
rRNA processing 3 2.992E-03
Generation of precursor
metabolites and energy
3 3.304E-03
Transmembrane receptor
protein tyrosine kinase
signaling pathway
3 4.085E-03
Nuclear mRNA splicing,
via spliceosome
3 1.079E-02
Intracellular protein transport 3 1.852E-02
Inflammatory response 3 2.545E-02
Gene Ontology classification performed by Onto-Express software. We reported
only significative biological processes ( p-valueb0.05) and with a number of
genes greater than 3.
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teolytic system. Mutations in the gene are responsible for an
osteochondrodysplasia named pycnodysostosis. An additional
cathepsin gene, CTSF, is up-regulated in MLIV fibroblasts.
Interestingly, gene expression profiling studies on a murine
model of another lysosomal storage disorder (mucopolysacchar-
idosis type VII) also show an up-regulation of a number of lyso-
somal enzymes [35].
Other lysosomal genes that are differentially expressed are not
directly involved in the pathogenesis of metabolic storage dis-
orders. Among them lysosomal-associated protein transmembrane
4A (LAPTM4A) and 5 (LAPTM5) genes, encoding multispanning
transmembrane proteins that reside in the late endosome/
lysosome. While LAPTM4A has a role in the transport of small
molecules across membranes of these organelles [36] the bio-
logical role of LAPTM5 is still unknown [37]. CD63 (also known
as LAMP-3) encodes for a membrane protein common to lyso-
somes, melanosomes, and platelet dense bodies [38].
3.4. Endosome to lysosome transport
The two up-regulated genes, EH-domain containing 1 (EHD1)
and EH-domain containing 3 (EHD3), take part to endocytic
process, in particular the EH domain has been shown to be an
important motif in proteins involved in protein–protein interac-
tions and in intracellular sorting. EHD1 interacts with EHD3 in
regulating the movement of recycling endocytic vesicles along
microtubule-dependent tubular tracks [39]. The protein encoded
by EHD1 is thought to play a role in the endocytosis of IGF1
receptor (IGF1R) [40]. Interestingly, IGF1R gene is 2.39 fold
more expressed in MLIV fibroblasts.
The VPS39 gene (also named hVam6p) is overexpressed 2.06
times inMLIV fibroblasts vs. controls. VPS39 exhibits homology
to the Saccharomyces cerevisiae vacuolar protein sorting gene
product Vam6p/Vps39p. Overexpression of VPS39 results in
massive clustering and fusion of lysosomes and late endosomes
into large (2–3 μm) juxtanuclear structures [41] that resemble to
the aberrant lysosomes inMLIV cells. The differential expression
of this gene observed in MLIV cells is particularly intriguing,
considering that studies carried out onC. elegans strongly suggesta defect in lysosome biogenesis in cells of worms with mutations
in the cup-5 homolog of the MCOLN1 gene [22].
3.5. Proton transport
Recently, it has been reported that the lysosomes ofMLIV cells
are more acidic than those of wild type cells and that MLN1
regulates lysosomal pH (pHL) [19]. The authors demonstrated that
MLN1 can function as a H+ channel, and the increased lysosomal
acidification in patients' cells is likely caused by the loss of
MLN1-mediated H+ leak. These results are in contrast with data
previously presented by Bach et al who reported elevated ly-
sosomal pH in mucolipidosis type IV cells [42]. pHL controls
most lysosomal hydrolytic activities and, above all, it's essential
for the normal function of lysosomes [43].
Interestingly, in our study we found overexpression of five
genes encoding for subunits of vacuolar ATPase (V-ATPase) in
MLIV fibroblasts (Table 5). V-ATPase is a multi-subunit enzyme
complex and a member of a family of ATP-driven proton pumps
responsible for the acidification of intracellular compartments such
as endosomes, lysosomes, Golgi-derived vesicles, and clathrin-
coated vesicles [44]. V-ATPase dependent organelle acidification
is necessary for such intracellular processes as protein sorting,
zymogen activation, receptor-mediated endocytosis, and synaptic
vesicle proton gradient generation. Our data suggest that the
overexpression of vacuolar ATPase subunits may also contribute
to the acidification described in lysosomes of MLIV patients.
3.6. Cholesterol and lipid metabolism
MLIV is characterized by accumulation of cholesterol and/
or glycosphingolipids in the endocytic compartments [7], a
phenomenon whose molecular basis is not well understood. It
has been hypothesized that the impaired endosomal/lysosomal
fusion limits access of lipids to lysosomal lipases leading to the
Table 5
List of differentially expressed genes related to biological and molecular processes altered in MLIV
Category Molecular function Gene symbol Entrez gene ID Fold change
Lysosome
Carrier activity CD63 967 2.84
Serine-type endopeptidase activity; tripeptidyl-peptidase I activity CLN2 1200 2.28
Chaperone activity CLN3 1201 3.39
Cysteine-type endopeptidase activity CTSF 8722 2.60
Cathepsin K activity CTSK 1513 6.82
Beta-N-acetylhexosaminidase activity HEXB 3074 2.60
L-iduronidase activity IDUA 3425 3.66
Nucleobase transporter activity LAPTM5 7805 7.57
Nucleobase transporter activity LAPTM4A 9741 2.99
Beta-mannosidase activity MANBA 4126 2.31
Receptor activity SCARB2 950 −2.04
Hydrolase activity; sphingomyelin phosphodiesterase activity SMPD1 6609 2.08
Electron transporter activity QSCN6 5768 3.29
Endocytosis
ATP binding; DNA binding; calcium ion binding EHD1 10938 2.57
ATP binding; DNA binding; calcium ion binding EHD3 30845 3.34
GTP binding RAB32 10981 2.46
Protein transporter activity; small GTPase Regulatory/interacting protein activity VPS39 23339 2.06
Proton transport
Hydrogen ion transporter activity; hydrolase activity ATP6V0D1 9114 2.39
Hydrogen-transporting ATPase activity\, rotational mechanism ATP6V0E 8992 2.50
ATP binding; hydrogen ion transporter activity; hydrolase activity ATP6AP1 537 2.00
Hydrogen ion transporter activity; hydrolase activity; receptor activity ATP6AP2 10159 2.00
Hydrogen-transporting ATP synthase activity\, rotational mechanism ATP6V0C 527 2.31
Cholesterol and lipid metabolism
Isopentenyl-diphosphate delta-isomerase activity; magnesium ion binding IDI1 3422 2.61
Dimethylallyltranstransferase activity; geranyltranstransferase activity FDPS 2224 2.61
Farnesyl-diphosphate farnesyltransferase activity; magnesium ion binding; FDFT1 2222 2.86
Oxidoreductase activity DHCR24 1718 2.87
RNA polymerase II transcription factor activity; protein binding SREBF2 6721 3.60
RNA polymerase II transcription factor activity; protein binding SREBF1 6720 3.33
Lipid transporter activity; low-density lipoprotein receptor activity LDLR 3949 7.57
Steroid hormone receptor activity; transcription factor activity PPARD 5467 2.38
Cell adhesion receptor activity ITGA4 3676 −3.34
Acetyl-CoA C-acetyltransferase activity ACAT1 38 −2.37
In the category column is reported the name of a GO grouping, either cell component or biological process.
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cate that mutation in MCOLN1 disrupts regulation of pHL [19]
which in turn may be responsible for the aberrant activity of
lysosomal lipases. This may explain the lysosomal accumulation
of lipids in MLIV cells. It is thus interesting that cholesterol and,
more generally, lipid metabolism emerged as one of the most
significative GO process category in our gene expression anal-
ysis, with a range of regulation from −3 to 7.5 fold (Table 5).
The low-density lipoprotein receptor (LDLR), 7.57-fold more
abundant in the MLIV pool, encodes a cell surface protein
involved in receptor-mediated endocytosis of specific ligands.
Low density lipoprotein (LDL) is normally bound at the cell
membrane and taken into the cell ending up in lysosomes where
the protein is degraded and the cholesterol is released. It has been
demonstrated that non physiological overexpression of low-
density lipoprotein receptors leads to the accumulation of large
amounts of LDL which eventually lead to massive intracellular
lipid deposition and the formation of crystal structures [46,47].
Interestingly, Jansen et al. performed a study that suggest thatMLIV fibroblasts have a defect that affects the low-density
lipoprotein-receptor-mediated endocytosis pathway [10].
SREBF1 and SREBF2 genes are both up-regulated in MLIV
fibroblasts. Sterol-regulatory element-binding proteins (SREBPs)
play a key role in transcriptional regulation of cholesterol metab-
olism in response to cholesterol levels in the cell [48]. Binding of
SREBPs to the LDLR promoter increases the expression of LDL
receptor on the cell surface and increases the internalization of
LDL from plasma, increasing cellular cholesterol levels and
lowering LDL cholesterol in the plasma. The up-regulation of
LDLR and SREBP genes observed in MLIV fibroblasts is con-
sistent with the model proposed for sphingolipid storage diseases
in which excess of sphingolipids in the endocytic compartments
serve as a “molecular trap” for cholesterol, leading to a reduction
in cholesterol at the endoplasmic reticulum, induction of sterol
regulatory element-binding protein-1 cleavage, and up-regulation
of LDL receptors [49].
This is the first study based on gene expression profiling on
mucolipidosis type IV.
257A. Bozzato et al. / Biochimica et Biophysica Acta 1782 (2008) 250–258In this analysis, carried out on fibroblast cell lines from three
MLIV patients, allowed us to detect the modulation at the
transcriptional level of a discrete number of genes belonging to
biological processes which are altered in the disease such as
endosome/lysosome trafficking, lysosome biogenesis, organelle
acidification and lipid metabolism. To support the validity of our
data, the differential expression of selected genes has been
mostly confirmed in biological samples from three other MLIV
patients.
In conclusion, we believe that the data presented in this study
will provide useful information for a better understanding of the
molecular mechanisms leading to mucolipidosis type IV.
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